BIOLOGY
纳安生物
Research area
Traditional tumor treatment is mainly based on surgery, chemotherapy, radiotherapy, etc., But although radiotherapy and chemotherapy can kill tumor cells, they also have a strong killing effect on normal cells; targeted therapy is based on cancer-related molecules as the target, drugs, antibodies and other active ingredients are targeted at cancer cells and related components, so as to achieve the purpose of treating cancer, less damage to normal cells, but there are still limitations such as immunogenicity, tumor heterogeneity, tumor microenvironment, and patient drug resistance.To this end, the organic combination of targeted drugs and chemotherapy drugs has achieved a new generation of anti-tumor drugs, called biological missile antibody-coupled drugs (ADCs), which use the targeting of antibody drugs to accurately target small molecule cytotoxic drugs to tumor tissue and release highly active cytotoxins to kill tumor cells; at the same time, the drug's accurate identification and targeted release of targets greatly reduces the toxic side effects of tumor chemotherapy.At present, 15 antibody-coupled drugs have been listed one after another in the world, and 6 have been approved for listing in my country.
Since its establishment in 2018, Nanolattix Biological has focused on the development of ADC (antibody drug conjugates) anti-cancer drugs.ADC drugs are unique in the field of cancer treatment with their advantages of precise treatment and low side effects.In recent years, cancer treatment methods have mainly focused on chemotherapy and targeted drug therapy, and ADC drugs have the advantages of both and are known as “biological missiles.”At present, there are 15 ADC drugs on the market worldwide, while there is only 1 ADC drug developed by our country.Nanolattix Biological's T320-ADC drug has the characteristics of accurately targeting a variety of malignant solid tumors, and has the independent intellectual property rights of T320, patent authorization, and significant medicinal properties.The success of this project not only fills the gap in the research and development of similar target ADC drugs in China, but also greatly enhances our country's international competitiveness in the field of ADC development. Nanolattix Biology has established a mature biomedical R&D platform, and multiple R&D pipelines are steadily advancing.
